CNS expands into UK, biometrics
Brisbane-based CRO Clinical Network Services (CNS) has expanded into Europe with the launch of a new office near London.
The company, which also serves the Australian and New Zealand clinical trials markets, has also launched a new biometrics service.
CNS has appointed Paul Cronin to lead up the new office as UK director and director of business development. Cronin has experience working with European regulatory consultancy companies.
Cronin will lead the European team providing CNS’s BioDesk product development planning and regulatory affairs service. BioDesk will help European clients interface with regulators in Europe, Australia and New Zealand.
CNS has also appointed Otto Damsma as director of biometrics and Glynn Morrish as pharmacometrician/biostatistician for its new biometrics service. Both appointees will work out of the company’s Brisbane headquarters.
Damsma led biometrics and IT at Yamanouchi/Astellas in Europe for more than a decade.
“These appointments have further expanded BioDesk’s ability to engage European regulators and to bring expert statistical and PK/PD modelling capabilities to early-stage product development,” CNS director of BioDesk and regulatory affairs Mark Reid said.
Cancer drug eliminates bone metastasis in lab models
Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...
TGA rejects Alzheimer's drug due to safety concerns
The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
